The company successfully completed its Series B financing round while simultaneously initiating HEROIC, its global Phase III (NCT07743671) clinical study evaluating engasertib (previously known as ALM 301) in patients with hereditary hemorrhagic telangiectasia (HHT). The Series B financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX. "Today represents a defining moment for HHT patients," said Azmi Nabulsi, president and CEO of Vaderis. "Closing this financing and initiating HEROIC as the first Phase III study utilizing a molecule specifically developed for HHT marks an exciting new chapter. Related:Sidewinder secure $137m Series B for oncology therapeutics“ This milestone reflects the dedication of our patients, investigators, study teams, and advocacy organizations, to whom we extend our deepest gratitude.